In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better understand sustained MRD-negativity.

BOTTOM LINE:
MRD-negative status is great for a myeloma patient to have, but it still does not mean the patient is cured.

Have a question? Submit it to [email protected]

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected].

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]

 

 

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
Cure Is the Primary Goal, But Let’s Not Forget Prevention
Next Post
Preview of the 9th Annual International Myeloma Working Group (IMWG) Summit

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.